Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: Discovery of deleobuvir (BI 207127)

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1845-1854

  LaPlante, Steven R ^a,b   Bös, Michael ^a   Brochu, Christian ^a   Chabot, Catherine ^a   Coulombe, René ^a   Gillard, James R ^a   Jakalian, Araz ^a   Poirier, Martin ^a   Rancourt, Jean ^a   Stammers, Timothy ^a   Thavonekham, Bounkham ^a   Beaulieu, Pierre L ^a   Kukolj, George ^a   Tsantrizos, Youla S ^a,c  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^b NMX Solutions   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; BI 207127; DELEOBUVIR; MOLECULAR SCAFFOLD;

ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG ANALYSIS; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; HEPATITIS C VIRUS; NONHUMAN; STRUCTURE ACTIVITY RELATION; TORSION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; HEPACIVIRUS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896311889     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4011862     Document Type: Article

References (66)

1. Teague, S. Implications of protein flexibility for drug discovery Nat. Rev. Drug Discovery 2003, 2, 527-541
2. Weikl, T. R.; von Deuster, C. Selected-fit versus induced-fit protein binding: Kinetic differences and mutational analysis Proteins: Struct., Funct., Bioinf. 2009, 75, 104-110
3. Hammes, G. G.; Chang, Y. C.; Oas, T. G. Conformational selection or induced fit: A flux description of reaction mechanism Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13737-13741
4. Bakan, A.; Bahar, I. The intrinsic dynamics of enzymes plays a dominant role in determining the structural changes induced upon inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 14349-14354
5. Lakomek, N. A.; Lange, O. F.; Oliver, F.; Walter, K. F.; Korvin, F. A.; Fares, C.; Egger, D.; Lunkenheimer, P.; Meiler, J.; Grubmueller, H.; Becker, S.; de Groot, B. L.; Griesinger, C. Residual dipolar couplings as a tool to study molecular recognition of ubiquitin Biochem. Soc. Trans. 2008, 36, 1433-1437
6. Lange, O. F.; Lakomek, N. A.; Fares, C.; Schroeder, G. F.; Gunnar, G.; Walter, K. F. A.; Becker, S.; Meiler, J.; Grubmueller, H.; Griesinger, C.; de Groot, B. L. Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution Science 2008, 320, 1471-1475
7. Kern, D.; Zuiderweg, E. R. The role of dynamics in allosteric regulation Curr. Opin. Struct. Biol. 2003, 13, 748-757
8. Mittermaier, A.; Kay, L. E. New tools provide new insights in NMR studies of protein dynamics Science 2006, 312, 224-228
9. Koshland, D. The active site and enzyme action Adv. Enzymol. Relat. Subj. Biochem. 1960, 22, 45-97
10. LaPlante, S. R.; Gillard, J. R.; Jakalian, A.; Aubry, N.; Coulombe, R.; Brochu, C.; Tsantrizos, Y. S.; Poirier, M.; Kukolj, G.; Beaulieu, P. L. Importance of ligand bioactive conformation in the discovery of potent indole-diamide inhibitors of the hepatitis C virus NS5B J. Am. Chem. Soc. 2010, 132, 15204-15212
11. 13C CSA-dipolar cross-correlated relaxation at natural abundance J. Am. Chem. Soc. 2003, 125, 11116-11130
12. 13C T1 relaxation at natural isotopic abundance: A practical method for determining site-specific changes in ligand flexibility upon binding to a macromolecule J. Am. Chem. Soc. 2000, 122, 12530-12535
13. 2 relaxation dispersion at natural abundance J. Biomol. NMR 2009, 45 (1-2) 171-183
14. Peng, J. W. Communication breakdown: Protein dynamics and drug design Structure 2009, 17, 319-320
15. Mauldin, R. V.; Carroll, M. J.; Lee, A. L. Dynamic dysfunction in dihydrofolate reductase results from antifolate drug binding: Modulation of dynamics within a structural state Structure 2009, 17, 386-394
16. Taylor, R. E.; Chen, Y.; Beatty, A.; Myles, D. C.; Zhou, Y. Conformation-activity relationships in polyketide natural products: A new perspective on the rational design of epothilone analogues J. Am. Chem. Soc. 2003, 125, 26-27
17. X analogues correlates with their affinity to E-selectin Angew. Chem., Int. Ed. 2001, 125, 1941-1945
18. Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking Proteins 1999, 37, 228-241
19. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Proteins 2003, 52, 609-623
20. Goodsell, D. S. Computational docking of biomolecular complexes with AutoDock CSH Protocols 2009, 2009 (pdb prot5200).
21. Morris, G. M.; Huey, R.; Olson, A. J. Using AutoDock for ligand-receptor docking. Current Protocols in Bioinformatics; Wiley: New York, 2008.
22. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases J. Comput.-Aided Mol. Des. 2001, 15, 411-428
23. McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, F. K. Gaussian docking functions Biopolymers 2003, 68, 76-90
24. Goto, J.; Kataoka, R.; Muta, H.; Hirayama, N. ASEDock-docking based on α spheres and excluded volumes J. Chem. Inf. Model. 2008, 48, 583-590
25. Tondel, K.; Anderssen, E.; Drablos, F. Protein Alpha Shape (PAS) Dock: A new gaussian-based score function suitable for docking in homology modeled protein structures J. Comput.-Aided Mol. Des. 2006, 20, 131-144
26. Jackson, S.; DeGrado, W.; Dwivedi, A.; Parthasarathy, A.; Higley, A.; Krywko, J.; Rockwell, A.; Markwalder, J.; Wells, G. Template-constrained cyclic peptides: Design of high-affinity ligands for GPIIb/IIIa J. Am. Chem. Soc. 1994, 116, 3220-3230
27. Miller, C. P.; Collini, M. D.; Harris, H. A. Constrained phytoestrogens and analogues as ERβ selective ligands Bioorg. Med. Chem. Lett. 2003, 13, 2399-2403
28. Udugamasooriya, D. G.; Spaller, M. R. Conformational constraint in protein ligand design and the inconsistency of binding entropy Biopolymers 2008, 89, 653-667
29. Sharma, R.; Lee, J.; Wang, S.; Milne, G. W. A.; Lewin, N. E.; Blumberg, P. M.; Marquez, V. E. Conformationally constrained analogues of diacylglycerol. 10. Ultrapotent protein kinase C ligands based on a racemic 5-disubstituted tetrahydro-2-furanone template J. Med. Chem. 1996, 39, 19-28
30. Martin, S. F. Preorganization in biological systems: Are conformational constraints worth the energy? Pure Appl. Chem. 2007, 79, 193-200
31. Harris, P. W. R.; Hügel, H. M.; Nurlawis, F. A review of the molecular conformations of melatonin ligands at the melatonin receptor Mol. Simul. 2002, 28, 889-902
32. Giebel, L. B.; Cass, R.; Milligan, D. L.; Young, D.; Arze, R.; Johnson, C. Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities Biochemistry 1995, 34, 15430-15435
33. Choo, Q.-L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 1989, 244, 359-362
34. Lavanchy, D. The global burden of hepatitis C Liver Int. 2009, 29, 74-81
35. O'Brien, C.; Godofsky, E.; Rodriguez-Torres, M.; Afdhal, N.; Pappas, S. C.; Pockros, P.; Lawitz, E.; Bzowej, N.; Rustgi, V.; Sulkowski, M.; Sherman, K.; Jacobson, I.; Chao, G.; Knox, S.; Pietropaolo, K.; Brown, N. A. Randomized trial of valopicitabine (NM283), alone or with peg-interferon, vs. retreatment with peg-interferon plus ribavirin (pegIFN/RBV) in hepatitis C patients with previous non-response to PegIFN/RBV: First interim results Hepatology 2005, 42, 234A
36. Brown, N. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues Expert Opin. Invest. Drugs 2009, 18, 709-725
37. Huang, Z.; Murray, M. G.; Secrist, J. A., III. Recent development of therapeutics for chronic HCV infection Antiviral Res. 2006, 71, 351-362
38. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S. L.; Poupart, M. A.; Lefebvre, S.; McKercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery and preliminary SAR of benzimidazole derivatives Bioorg. Med. Chem. Lett. 2004, 14, 119-124
39. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; Poupart, M.-A.; Valois, S.; McKercher, G.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency Bioorg. Med. Chem. Lett. 2004, 14, 967-971
40. Beaulieu, P. L.; Gillard, J.; Bykowski, D.; Brochu, C.; Dansereau, N.; Duceppe, J. S.; Haché, B.; Jakalian, A.; Lagacé, L.; LaPlante, S. R.; McKercher, G.; Moreau, E.; Perreault, S.; Stammers, T.; Thauvette, L.; Warrington, J.; Kukolj, G. Improved replicon cellular activity of non-nucleoside allosteric inhibitors of HCV NS5B polymerase: From benzimidazole to indole scaffolds Bioorg. Med. Chem. Lett. 2006, 16, 4987-4993
41. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerin, C.; Valois, S.; Kukolj, G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: Inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells J. Med. Chem. 2004, 47, 6884-6892
42. Kukolj, G.; McGibbon, G.; McKercher, G.; Marquis, M.; Lefebvre, S.; Thauvette, L.; Gauthier, J.; Goulet, S.; Poupart, M. A.; Beaulieu, P. L. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase J. Biol. Chem. 2005, 280, 39260-39267
43. Goulet, S.; Poupart, M. A.; Gillard, J.; Poirier, M.; Kukolj, G.; Beaulieu, P. L. Discovery of benzimidazole-diamide finger loop (thumb pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization Bioorg. Med. Chem. Lett. 2010, 20, 196-200
44. McKercher, G.; Beaulieu, P. L.; Lamarre, D.; LaPlante, S. R.; LeFebvre, S.; Pellerin, C.; Thauvette, L.; Kukolj, G. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate Nucleic Acids Res. 2004, 32, 422-431
45. LaPlante, S. R.; Jakalian, A.; Aubry, N.; Bousquet, Y.; Ferland, J. M.; Gillard, J.; Lefebvre, S.; Poirier, M.; Tsantrizos, Y. S.; Kukolj, G.; Beaulieu, P. L. Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy Angew. Chem., Int. Ed. 2004, 43, 4306-4311
46. Beaulieu, P. L.; Bös, M.; Cordingley, M. G.; Chabot, C.; Fazal, G.; Garneau, M.; Gillard, J. R.; Jolicoeur, E.; LaPlante, S.; McKercher, G.; Poirier, M.; Poupart, M.-A.; Tsantrizos, Y. S.; Duan, J.; Kukolj, G. Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV) J. Med. Chem. 2012, 55, 7650-7666
47. Erhardt, A.; Deterding, K.; Benhamou, Y.; Reiser, M.; Forns, X.; Pol, S.; Calleja, J. L.; Ross, S.; Spangenberg, H. C.; Garcia-Samaniego, J.; Fuchs, M.; Enriquez, J.; Wiegand, J.; Stern, J.; Wu, K.; Kukolj, G.; Marquis, M.; Beaulieu, P.; Nehmiz, G.; Steffgen, J. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment Antiviral Ther. 2009, 14, 23-32
48. Beaulieu, P. L. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection Expert Opin. Ther. Pat. 2009, 19, 145-164
49. Beaulieu, P. L. Successful strategies for the discovery of antiviral drugs; Desai, M.; Meanwell, N., Eds.; RSC Drug Discovery Series 32; The Royal Society of Chemistry: London, 2013; Chapter 9, p 279.
50. Ikegashira, K.; Oka, T.; Hirashima, S.; Noji, S.; Yamanaka, H.; Hara, Y.; Adachi, T.; Tsuruha, J.-I.; Doi, S.; Hase, Y.; Noguchi, T.; Ando, I.; Ogura, N.; Ikeda, S.; Hashimoto, H. Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors J. Med. Chem. 2006, 49, 6950-6953
51. Stanfield, I.; Ercolani, C.; Mackay, A.; Conte, I.; Pompei, M.; Koch, U.; Gennari, N.; Giuliano, C.; Rowley, M.; Narjes, F. Tetracyclic indole inhibitors of hepatitis C virus NS5B-polymerase Bioorg. Med. Chem. Lett. 2009, 19, 627-632
52. Habermann, J.; Capito, E.; del Rosario Rico, M.; Ferreira, U.; Koch, U.; Narjes, F. Discovery of pentacyclic compounds as potent inhibitors of hepatitis C virus NS5B RNA polymerase Bioorg. Med. Chem. Lett. 2009, 19, 633-638
53. Ding, M.; He, F.; Hudyma, T. W.; Zheng, X.; Poss, M. A.; Kadow, J. F.; Beno, B. R.; Rigat, K. L.; Wang, Y. K.; Fridell, R. A.; Lemm, J. A.; Qiu, D.; Liu, M.; Voss, S.; Pelosi, L. A.; Roberts, S. B.; Gao, M.; Knipe, J.; Gentles, R. Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: Potent allosteric inhibitors of the hepatitis C virus NS5B polymerase Bioorg. Med. Chem. Lett. 2012, 22, 2866-2871
54. Vendeville, S.; Lin, T.-I.; Hu, L.; Tahri, A.; McGowan, D.; Cummings, D.; Amssoms, K.; Canard, M.; Last, S.; van den Steen, I.; Devogelaere, B.; Rouan, M.-C.; Vijgen, L.; Berke, J. M.; Dehertogh, P.; Fransen, E.; Cleiren, E.; van der Helm, L.; Fanning, G.; van Emelen, K.; Nyanguile, O.; Simmen, K.; Raboisson, P. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055 Bioorg. Med. Chem. Lett. 2012, 22, 4437-4443
55. Cummings, M. D.; Lin, T.-I.; Hu, L.; Tahri, A.; McGowan, D.; Amssoms, K.; Last, S.; Devogelaere, B.; Rouan, M.-C.; Vijgen, L.; Berke, J. M.; Dehertogh, P.; Fransen, E.; Cleiren, E.; van der Helm, L.; Fanning, G.; van Emelen, K.; Nyanguile, O.; Simmen, K.; Raboisson, P.; Vendeville, S. Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties Angew. Chem., Int. Ed. 2012, 51, 4637-4640
56. Larry, D.; Benhamou, Y.; Lohse, A. W.; Trepo, C.; Moelleken, C.; Bronowicki, J.-P.; Arasteh, K.; Bourliere, M.; Heim, M.; Enriquez, J.; Erhardt, A.; Zarski, J. P.; Wiest, R.; Gerlach, T.; Wedemeyer, H.; Berg, T.; Stern, J.; Wu, K.; Abdallah, N.; Nehmiz, G.; Boecher, W.; Steffgen, J. Safety, Pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C J. Hepatol. 2009, 50 (Suppl. 1) S383-S384, Abstract 1054
57. Zeuzem, S.; Asselah, S.; Angus, P.; Zarski, J.-P.; Larrey, D.; Mullhaupt, H.; Gane, E.; Schuchmann, M.; Lohse, A.; Pol, S.; Bronowicki, J.-P.; Roberts, S.; Arasteth, A.; Zoulim, A.; Heim, M.; Stern, J. O.; Kukolj, G.; Nehmiz, H.; Haefner, C.; Boecher, W. O. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 2011, 141, 2047-2055
58. Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.-P.; Lohse, A.; Müllhaupt, B.; Schuchmann, M.; Bourliere, M.; Buti, M.; Roberts, S.; Gane, E.; Stern, J. O.; Kukolj, G.; Dai, L.; Böcher, W. O.; Mensa, F. J. SVR4 and SVR12 with an interferon-free regimen of BI201335 AND BI207127, +/- ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2 J. Hepatol. 2012, 56 (Suppl. 2) S45
59. Zeuzem, S.; Soriano, V.; Asselah, T.; Bronowicki, J.-P.; Lohse, A. W.; Müllhaupt, B.; Schuchmann, M.; Bourlière, M.; Buti, M.; Roberts, S. K.; Gane, E. J.; Stern, J. O.; Vinisko, R.; Kukolj, G.; Gallivan, J.-P.; Böcher, W.-O.; Mensa, F. J. Faldaprevir and deleobuvir for HCV genotype 1 infection N. Engl. J. Med. 2013, 369, 630-639
60. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591
61. Vaillancourt, F. H.; Pilote, L.; Cartier, M.; Lippens, J.; Liuzzi, M.; Bethell, R. C.; Cordingley, M. G.; Kukolj, G. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication Virology 2009, 387, 5-10
62. Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Piorier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J. Viral Polymerase Inhibitors. Patent WO 03/010141, 2003.
63. LaPlante, S. R.; Aubry, N.; Bonneau, P.; Kukolj, G.; Lamarre, D.; Lefebvre, S.; Li, H.; Llinàs-Brunet, M.; Plouffe, C.; Cameron, D. R. NMR line-broadening and transferred NOESY as a medicinal chemistry tool for studying inhibitors of the hepatitis C virus NS3 protease domain Bioorg. Med. Chem. Lett. 2000, 10, 2271-2274
64. Beaulieu, P. L.; Anderson, P. C.; Bös, M.; Brochu, C.; Cordingley, M. G.; Duan, J.; Garneau, M.; Lagacé, L.; LaPlante, S. R.; Marquis, M.; McKercher, G.; Poupart, M.-A.; Rancourt, J.; Stammers, T.; Tsantrizos, Y. S.; Kukolj, G. Preclinical characterization of the hepatitis C virus NS5B polymerase non-nucleoside inhibitor BI 207127. 19th International Symposium on Hepatitis C Virus and Related Viruses, October 5-9, 2012, Venice, Italy.
65. Duan, J.; Bolger, G.; Garneau, M.; Amad, M.; Batonga, J.; Montpetit, H.; Otis, F.; Jutras, M.; Lapeyre, N.; Rhéaume, M.; Kukolj, G.; White, P. W.; Bethell, R. C.; Cordingley, M. G. The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans Antimicrob. Agents Chemother. 2012, 56, 5381-5386
66. LaPlante, S. R.; Cameron, D. R.; Aubry, N.; Lefebvre, S.; Kukolj, G.; Maurice, R.; Thibeault, D.; Lamarre, D.; Llinàs-Brunet, M. Solution Structure of Substrate-based Ligands When Bound to Hepatitis C Virus NS3 Protease Domain J. Biol. Chem. 1998, 274, 18618-18624